Summary

Chemoradiotherapy is not superior to chemotherapy and the addition of erlotinib provides no benefit in the treatment of locally advanced pancreatic cancer. This article presents data from the Randomized Multicenter Phase 3 Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas [LAP07; NCT00634725; Hammel P et al. J Clin Oncol 2013 (suppl; abstr LBA4003)].